ReviewPharmaceutics2023
Off-Label Prescribing in Pediatric Population-Literature Review for 2012-2022.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Off-Label Medicine Use in Pediatric Anesthesia-Recommendations of the World Federation of Societies of Anaesthesiologists (WFSA) Paediatric Committee.Paediatric anaesthesia · 2026Guideline
- Stewardship Challenges, PK/PD Evidence, and Prescribing Appropriateness for Recently Approved Antibiotics in Pediatric Practice.Antibiotics (Basel, Switzerland) · 2026Review
- Plasma Lidocaine Concentrations During Intravenous Lidocaine Infusion Therapy in the Pediatric Population-A Scoping Review.Paediatric anaesthesia · 2026Article
- Age-Appropriateness of Oral Formulations Authorized for Pediatrics.Pharmaceutical research · 2026Article
- Serious Adverse Drug Reactions Associated with Off-Label and Unlicensed Drug Use in Children: A 14-Year Analysis of VigiBase Reports from Serbia.Children (Basel, Switzerland) · 2026Article
- Prescription of vitamin D in neonates and infants under one year of age in Spain: an eight-year observational study.BMC primary care · 2026Observational
- Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities.Pharmaceutics · 2026Review
- Off-label prescribing in Italian pediatric practice: insights from a nationwide survey.European journal of pediatrics · 2025Article
- Evaluation of Research and Scholarship Activities with a Pediatric Curricular Track in a Doctor of Pharmacy Program.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- The importance of patient engagement when promoting age-inclusive research.Research involvement and engagement · 2025Article
- Ethical considerations in AI for child health and recommendations for child-centered medical AI.NPJ digital medicine · 2025Review
- Mapping the therapeutic versatility of WHO essential medicines: a systematic analysis of off-label indications.Therapeutic advances in drug safety · 2025Article
- A close examination of BCRP's role in lactation and methods for predicting drug distribution into milk.CPT: pharmacometrics & systems pharmacology · 2024Review
- Oral Gels as an Alternative to Liquid Pediatric Suspensions Compounded from Commercial Tablets.Pharmaceutics · 2024Article
- Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024.Obesity pillars · 2024Article
- Article
- Younger Children with Respiratory Tract Infections Are More Exposed to Off-Label Treatments: An Exploratory Retrospective Study in a Pediatric Emergency Setting.Children (Basel, Switzerland) · 2024Article
- Ingestion of Fluids of the Ocular Surface Containing Eye Drops of Imidazole Derivatives-Alpha Adrenergic Receptor Agonists as Paragons.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Paediatric formulations-part of the repurposing concept?Frontiers in medicine · 2024Article
- Effects of the Paediatric Regulation funding on the development of off-patent medicines in children.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Off-label prescribing is widespread among pediatricians, and it is unlikely that this trend will soon be bound by a uniform legal framework. This is necessitated by the fact that there are four variables: the patient's health condition, the physician's experience and knowledge, the legislative measures (laws, directives, guidelines, and recommendations), and finally, the pharmaceutical industry. There is considerable concern worldwide about the use of off-label medicines in children. We may call it an enormous global problem that is much talked about and written about; however, we should not forget that the goal around which everyone should unite is the patient's life. For healthcare providers, the most important thing will always be the health and preservation of the patient's life, particularly when it comes to children with life-threatening conditions in neonatal and pediatric intensive care units (NICU and PICU). The study aimed to examine the prevalence of off-label drug use in pediatrics. Literature research was conducted, and we included studies from 2012 to 2022 that evaluated off-label drug prevalence in various pediatric patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.